Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data ABEONA THERAPEUTICS INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
2.35
0.84
3
10
3
1.41
3.5
5.82
Cost of revenue
1.53
Gross profit
4.29
Research and development
10.7
17
38.7
48.6
30.1
38.7
29
31.1
34.4
26.8
Selling, general and administrative
29.9
65
General and administrative
13.3
10.9
20.1
20.7
23.8
21.6
17.3
19
29.9
65
Operating expenses
28.7
61.2
77.1
91.4
92.8
52.3
50.6
64.2
Operating income
-23.9
-27.8
-58.2
-77.1
-81.4
-89.8
-50.9
-47.1
-64.2
-89.4
Interest expense
4.12
3.66
0.74
0.42
4.21
3.74
Other non-operating income
2.01
0.52
0.14
2.94
1.19
0.41
Pre-tax income
-63.7
71.3
Income tax
0
0
0
0.1
Net income
-21.9
-27.3
-56.7
-76.3
-84.2
-84.9
-39.7
-54.2
-63.7
71.2
EBITDA
-23.1
-27.1
-55.8
-69.3
-76.8
-86.6
-47.8
-44.8
-62.2
-86.9
EPS, basic
-0.64
-0.66
-1.19
-1.51
-0.91
-21.57
-5.53
-2.53
-1.55
1.34
EPS, diluted
-0.64
-0.66
-1.19
-1.51
-0.91
-0.86
-5.53
-2.53
-1.55
1.01
Shares, basic (weighted)
34.2
41.6
47.5
50.4
92.7
3.94
7.86
21.4
41
53
Shares, diluted (weighted)
34.2
41.6
47.5
50.4
92.7
98.4
7.86
21.4
41
66.1
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
69.1
138
18.8
129
12.6
32.9
14.2
14.5
23.4
78.4
Short-term investments
0
66.2
82.4
12.1
37.9
37.8
74.4
113
Receivables
0.12
0.11
0.08
3
6.15
Inventory
5.49
Other current assets
0.16
2.74
3.8
3.13
2.71
2.38
0.42
0.73
1.14
1.29
Total current assets
69.4
141
88.9
132
97.7
56.3
53.1
55.7
101
205
Property, plant and equipment
0.72
1.37
9.44
13.2
11.3
12.3
5.74
3.53
4.43
9.92
Lease right-of-use assets
8.05
7.03
9.4
5.33
4.46
3.55
3.96
Goodwill
32.5
32.5
32.5
32.5
32.5
Intangible assets
8.38
3.98
43
36.2
1.5
1.38
0
Other non-current assets
0.17
0.04
0.28
0.1
0.78
Total assets
111
179
174
223
151
79.6
64.2
64
109
220
Accounts payable
3.69
1.88
6.12
3.76
4.7
4.33
1.81
1.86
3.44
7.89
Accrued liabilities
0.51
3.94
5.54
3.41
5.59
3.99
5.99
6.33
8.47
Deferred revenue
0.6
2.6
0.3
0.3
0.3
0.3
Short-term debt
5.93
12.2
Total current liabilities
8.3
5.61
20.4
38.7
42
16.6
7.78
13.4
16.6
29.6
Long-term debt
13
7.81
Lease liabilities
6.25
5.26
7.56
5.85
4.4
3.26
4.07
Other non-current liabilities
0.2
Total liabilities
12
8.67
40.4
45
48.6
37.2
37.5
49.2
64.9
60.4
Total debt
19
20
Paid-in capital
431
529
544
664
672
697
722
764
857
901
Retained earnings
-332
-360
-410
-486
-571
-656
-695
-750
-813
-742
Other comprehensive income
-0.01
-0.03
-0.13
-0.07
0.01
0.14
Shareholders' equity
99.1
170
134
178
103
42.4
26.8
14.8
44
159
Total equity
99.1
170
134
178
103
42.4
26.8
14.8
44
159
Total liabilities and equity
111
179
174
223
151
79.6
64.2
64
109
220
Shares outstanding
40.3
46.9
47.9
83.6
96.1
5.89
17.7
26.5
45.6
55
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-21.9
-27.3
-56.7
-76.3
-84.2
-84.9
-39.7
-54.2
-63.7
71.2
Depreciation and amortization
0.83
0.74
2.36
7.82
4.59
3.25
3.09
2.29
2
2.55
Stock-based compensation
4.83
4.64
8.18
7.34
5.85
8.92
3.05
4.77
6.63
10.8
Change in receivables
-0.01
0.02
0.03
0.08
-3
3
-6.15
Change in inventory
-5.49
Change in payables
2.82
-1.3
7.67
0.83
-4.11
2.04
1.51
6.54
Cash from operations
-13
-22.7
-39.1
-62.8
-35
-65.7
-43.5
-37
-56
-76.3
Capital expenditures
-0.52
-0.86
-9.24
-6.31
-1.34
-4.15
-0.13
-0.33
-2.45
-7.98
Purchases of investments
0
0
-136
-170
-20.2
-78.2
-51.6
-157
-207
Sales and maturities of investments
0
0
70.5
152
Cash from investing
-0.52
-0.86
-85.1
60
-83.7
66.1
-24
0.21
-39.2
105
Debt issued
20
Stock issued
0.35
0.34
2.24
17
0.18
8.05
12.8
14.4
15.5
17.3
Cash from financing
42.5
92.4
5.48
114
1.94
24.9
43.2
37.1
104
26
Net change in cash
29
68.9
-119
111
-117
25.3
-24.3
0.26
8.88
54.7
Free cash flow
-13.5
-23.5
-48.4
-69.1
-36.4
-69.8
-43.6
-37.3
-58.5
-84.3
Interest paid
0.01
0.01
0.01
2.67
2.59
Income taxes paid
0.01
0.01
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $5.40 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
67.1%
Gross profit / revenue.
Operating margin
-327.6%
Operating income / revenue.
EBITDA margin
-316.5%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-306.8%
Pre-tax income / revenue.
Net margin
-246.4%
Net income / revenue.
FCF margin
-319.5%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-299.5%
Cash from operations / revenue.
Return on equity (ROE)
-49.1%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-35.0%
Net income / average total assets.
Return on invested capital (ROIC)
-76.1%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
99.9%
Research and development expense / revenue.
SG&A / revenue
287.7%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
45.4%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
19.9%
Capital expenditures / revenue.
D&A / revenue
11.2%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue CAGR, 3y
60.3%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-10.3%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
261.6%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
81.2%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
9.2%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
101.6%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
50.7%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
7.7%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
61.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
103.4%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
-6.5%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
6.63x
Current assets / current liabilities.
Quick ratio
6.30x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
5.92x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.12x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
8.3%
Total debt / total assets.
Liabilities / assets
28.7%
Total liabilities / total assets.
Net debt
-$131.8M
Total debt - cash - short-term investments. Negative means more cash than debt.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$1.10
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.45
Revenue / diluted weighted shares.
FCF per share
-$1.43
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$1.34
Cash from operations / diluted weighted shares.
Book value per share
$2.24
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
12.1x
Market cap / revenue.
P/B
2.41x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
2.41x
Market cap / tangible book value, when positive.
EV/Sales
6.93x
Enterprise value / revenue.
FCF yield
-26.4%
Free cash flow / market cap.
Earnings yield
-20.4%
Net income / market cap (the inverse of P/E).
What was ABEONA THERAPEUTICS INC.'s revenue in fiscal 2025?
ABEONA THERAPEUTICS INC. reported revenue of $5.8M for fiscal 2025.
Was ABEONA THERAPEUTICS INC. profitable in fiscal 2025?
Yes. Net income was $71.2M, a net margin of 1,223.1%.
How much free cash flow did ABEONA THERAPEUTICS INC. generate in fiscal 2025?
Cash from operations of $76.3M minus capital expenditures of $8.0M left free cash flow of -$84.3M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.